Table 3.
Sensitivity and specificity of alpha-fetoprotein and prothrombin induced by vitamin K absence-II in differentiating hepatocellular carcinoma from nonmalignant chronic hepatitis B
| Sensitivity | Specificity | PPV | NPV | |
| PIVKA-II (mAU/mL) | ||||
| > 40 | ||||
| HCC vs CHB | 73.9% | 89.7% | 50.7% | 96.0% |
| HCC vs LC | 73.9% | 90.4% | 84.7% | 82.8% |
| > 100 | ||||
| HCC vs CHB | 57.3% | 98.8% | 87.4% | 94.2% |
| HCC vs LC | 57.3% | 96.8% | 82.8% | 76.0% |
| > 125 | ||||
| HCC vs CHB | 56.1% | 99.2% | 90.7% | 94.0% |
| HCC vs LC | 56.1% | 97.3% | 93.6% | 75.5% |
| > 150 | ||||
| HCC vs CHB | 52.9% | 99.4% | 92.2% | 93.6% |
| HCC vs LC | 52.9% | 97.3% | 93.3% | 74.2% |
| AFP (ng/mL) | ||||
| > 10 | ||||
| HCC vs CHB | 67.5% | 90.3% | 50.0% | 95.1% |
| HCC vs LC | 67.5% | 82.6% | 73.6% | 78.0% |
| > 20 | ||||
| HCC vs CHB | 59.9% | 94.4% | 60.3% | 94.3% |
| HCC vs LC | 59.9% | 90.0% | 81.0% | 75.8% |
| > 200 | ||||
| HCC vs CHB | 36.3% | 99.3% | 87.7% | 91.6% |
| HCC vs LC | 36.3% | 99.1% | 96.6% | 68.5% |
| > 400 | ||||
| HCC vs CHB | 29.9% | 99.7% | 94.0% | 90.9% |
| HCC vs LC | 29.9% | 100.0% | 100.0% | 66.6% |
| Combination1 | ||||
| HCC vs CHB | 75.2% | 95.4% | 69.8% | 96.4% |
| HCC vs LC | 75.2% | 92.7% | 88.1% | 83.9% |
1
Combination obtained from variable logAFP + 4.61logPIVKA-II. PPV: Positive predictive value; NPV: Negative predictive value; PIVKA-II: Prothrombin induced by vitamin K absence-II; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; LC: Liver cirrhosis; AFP: Alpha-fetoprotein.